Biomarker ID | 1620 |
PMID | 31035590 |
Year | 2019 |
Biomarker | MMP9 [SNP: rs3918262; A Vs G] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 4.31 (95% CI: 1.81–10.26) |
Effect on Pathways | Pathways include: Syndecan 1 pathway, Gastrin pathway, Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling, TWEAK signaling pathway, Endochondral ossification |
Experiment | Overall Survival Vs No Overall Survival |
Type of Biomarker | Prognostic |
Cohort | 418 patients in the training cohort (76 died) and 131 patients in the validation cohort (25 died) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.001 |
Method Used | Allele specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |